Skip to main content

Viatris Inc Influvac ® revenue

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

Influvac ® revenue at Viatris Inc came to $90.6M for the quarter to 30 Sep 2026, down 27.8% from a year earlier.

As Viatris Inc reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.

By quarter

$161.2MSep 2021$159.3MSep 2022$137.2MSep 2023$121.3MSep 2024$125.4MSep 2025$90.6MSep 2026
Viatris Inc Influvac ® revenue, every reported period
Period endingInfluvac ® revenueChange on a yearFiled
30 Sep 2026$90.6Mdown 27.8%5 Nov 2026
30 Sep 2025$125.4Mup 3.4%6 Nov 2025
30 Sep 2024$121.3Mdown 11.6%7 Nov 2024
30 Sep 2023$137.2Mdown 13.9%8 Nov 2023
30 Sep 2022$159.3Mdown 1.2%7 Nov 2022
30 Sep 2021$161.2M—8 Nov 2021

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Viatris Inc: Brands revenue · Generics revenue · Lipitor revenue · Norvasc revenue · EpiPen® Auto-Injectors revenue · Lyrica ® revenue · Creon ® revenue · Viagra ® revenue · Zoloft ® revenue · Yupelri ® revenue · Celebrex ® revenue · Effexor ® revenue · Xalabrands revenue · Xanax ® revenue · Amitiza ® revenue · Dymista ® revenue · Developed Markets Segment revenue · Greater China revenue · Emerging Markets Segment revenue · Japan, Australia and New Zealand Segment revenue · financial statements

Every KPI and segment of VTRS, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.